MYELODYSPLASTIC SYNDROMES

This early-phase study tests whether the oral drug Inqovi (decitabine/cedazuridine) can reduce the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplan…

This study tests whether eltrombopag, a drug that boosts platelet production, can help adults with lower-risk myelodysplastic syndromes (MDS) who rely on platelet transfusions. About 36 Japanese participants will receive either eltrombopag or a placebo. The main goal is to see if…

This study tests a way to make stem cell transplants safer for people with blood cancers or immune disorders who don't have a fully matched donor. By removing certain immune cells from the donated cells, doctors hope to lower the risk of graft-versus-host disease, a serious compl…

This study tests a drug called luspatercept in 70 adults with a low-risk form of myelodysplastic syndromes (MDS) that includes ring sideroblasts. The goal is to see if the drug can reduce or eliminate the need for red blood cell transfusions. Participants receive the drug as an i…

This early-stage study tests whether adding canakinumab to a standard anemia drug (darbepoetin alfa) can help people with lower-risk myelodysplastic syndromes (MDS) who no longer respond to standard treatment. The goal is to reduce or eliminate the need for blood transfusions. Ab…

This early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for long-term immune-suppressing medications after a stem cell transplant. The trial involves 32 older adults (age 60+) with certain…

This study is testing a chemotherapy drug called CPX-351 in 20 adults aged 18-70 with higher-risk myelodysplastic syndrome (MDS) who are candidates for a stem cell transplant. The main goal is to see if the drug is safe and tolerable at two different dose levels. Researchers will…

This study tests whether adding a precise, high-dose radiation to the whole marrow before a stem cell transplant can help people with high-risk acute myeloid leukemia or myelodysplastic syndromes live longer without their cancer coming back. About 38 adults aged 18-65 will receiv…

This study tests whether stem cells from donated umbilical cords are safe and can help people with myelodysplastic syndrome (MDS), a bone marrow disorder. About 40 adults with moderate to severe MDS will receive the stem cells and be watched for side effects and improvement. The …

This study tests an oral drug called azacitidine (ONUREG) in people with low- or intermediate-risk myelodysplastic syndrome (MDS), a blood disorder where the bone marrow doesn't make enough healthy blood cells. About 230 participants will receive either the drug or a placebo, alo…

This study provides ongoing treatment with the drug ASTX727 for people with certain blood cancers (acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes) who were already benefiting from it in earlier studies. About 332 participants will continue t…

This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug (ipilimumab) to help fight the cancer. The …

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, teens, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vorinost…

This study looks at whether adding a palliative care team to standard leukemia treatment helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life planning. About 320 adults receiving non-intensive therapy will be ran…

This study looks at whether a lab test can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers will test blood samples before treatment to see if the results match how patients actually respond. The g…

This study was designed to learn how the protein calprotectin changes blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare cells from patients and healthy adults in lab tests. However, the study was withdrawn before any particip…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict recovery and complications after transplant. The goal is to better understand the role of muscle strength in patient o…

This study follows 300 people with persistent low blood cell counts that are not yet diagnosed as myelodysplastic syndromes (MDS). The goal is to track how often these pre-MDS conditions (called ICUS and CCUS) turn into MDS over time. Participants will be monitored regularly, but…

This study aims to understand the genetic and molecular changes that happen in people with bone marrow failure disorders, such as aplastic anemia and myelodysplastic syndromes. Researchers will analyze blood and bone marrow samples from up to 1,400 participants, including healthy…